Breathe Easier: How Omalizumab Can Transform Severe Allergic Asthma
"A 5-Year Study Reveals the Life-Changing Impact of Omalizumab on Asthma Control, Exacerbations, and Steroid Use"
Asthma, a chronic condition characterized by inflamed and constricted airways, affects millions worldwide. While various treatments exist, some individuals with severe allergic asthma struggle to achieve adequate control, leading to frequent exacerbations and a diminished quality of life. For these individuals, a targeted therapy like omalizumab may offer renewed hope.
Omalizumab, a humanized anti-IgE monoclonal antibody, works by neutralizing immunoglobulin E (IgE) in the body. IgE plays a central role in allergic reactions, triggering the release of inflammatory mediators that contribute to asthma symptoms. By blocking IgE, omalizumab can reduce inflammation, improve lung function, and decrease the frequency of asthma attacks.
A recent single-center observational study investigated the long-term impact of omalizumab on patients with severe allergic asthma. The study, which followed patients for five years, revealed remarkable improvements in asthma control, a significant reduction in asthma exacerbations, decreased oral corticosteroid use, and improved lung function. Let's delve into the findings of this study and explore how omalizumab can transform the lives of those living with severe allergic asthma.
Treatment Steps and the Limits of IgE-Based Assessment
Guidelines identify five treatment steps for adults and children, and severe asthma exacerbations can be life-threatening. Omalizumab (Xolair) is a recombinant DNA-derived humanized monoclonal antibody indicated as add-on therapy for patients aged 6 years and older with severe persistent allergic asthma uncontrolled at treatment step 4 or 5. Reviews report that it has reduced exacerbations and corticosteroid use in trials and real-world studies. However, the extent to which IgE contributes to asthma in an individual patient remains unclear, and existing serum-IgE and intradermal diagnostic methods for atopic asthma have limitations.
Omalizumab: A Long-Term Game Changer for Asthma Control?
The five-year observational study provides compelling evidence for the long-term benefits of omalizumab in patients with severe allergic asthma. The study, conducted at a respiratory unit in Italy, involved 15 outpatients with severe allergic asthma who received omalizumab treatment for at least five years. Researchers closely monitored various parameters, including asthma control test (ACT) scores, the number of annual asthma exacerbations, oral corticosteroid intake, lung function, and blood eosinophil counts.
- Improved Asthma Control: ACT scores, which assess asthma control, increased significantly after one year and five years of omalizumab treatment, indicating better symptom management and improved quality of life.
- Reduced Exacerbations: Omalizumab dramatically reduced the number of annual asthma exacerbations, decreasing the need for emergency room visits and hospitalizations.
- Lowered Steroid Use: The study found that omalizumab enabled many patients to reduce or even eliminate their reliance on oral corticosteroids, which are often associated with significant side effects.
- Enhanced Lung Function: Omalizumab significantly and persistently improved lung function, as measured by FEV1 (forced expiratory volume in one second).
- Reduced Eosinophils: The treatment led to a reduction in blood eosinophil counts, indicating decreased airway inflammation.
Real-World Findings on Omalizumab
A 2021 systematic review examined oral-corticosteroid dependence and biologic drugs in severe asthma using real-world evidence, including reports on omalizumab. One included five-year, single-center observational study from Italy followed 15 people with severe allergic asthma; the source snippet reports values of 46.6, 33.3, 22.5, −20.7, and 73.3 for its listed outcome columns. A real-life study of omalizumab in severe allergic asthma and nasal polyps also reports that omalizumab decreased blood eosinophil counts in treated patients with severe allergic asthma. The available snippets do not provide enough detail to interpret all the reported study values or establish how broadly the findings apply.
Response Is Not Universal
Omalizumab does not bring every patient with severe allergic asthma to disease control: one study reported that approximately 60% achieved control. An observational retrospective cohort study assessed response in three ways—lower oral-corticosteroid use, improved lung function, and fewer exacerbations—underscoring that response can be evaluated across distinct outcomes. At the same time, a 2025 overview described omalizumab as a foundational biologic therapy for moderate-to-severe allergic asthma, particularly for patients with elevated IgE and allergic sensitization. These sources support its role while indicating that outcomes vary and depend on the measure and patient group considered.
A Brighter Future for Severe Allergic Asthma Sufferers?
The five-year observational study offers hope for individuals with severe allergic asthma who struggle to achieve adequate control with conventional treatments. Omalizumab has demonstrated its ability to improve asthma control, reduce exacerbations, lower steroid use, and enhance lung function.
Real-Life Evidence Across Varied Settings
Omalizumab targets IgE, a mechanism common in allergic diseases including severe allergic asthma, and may be particularly beneficial for patients with severe allergic asthma and multiple allergic conditions. A meta-analysis of noncontrolled real-life studies examined omalizumab as add-on treatment to inhaled corticosteroids, with or without long-acting beta-2 agonists, in patients with severe allergic asthma. Its authors described evidence of improved outcomes across heterogeneous patients, clinicians, sites, and treatment patterns. A separate real-world meta-analysis assessed treatment response, lung function, exacerbations, oral corticosteroid use, patient-reported outcomes, health care resource utilization, and school or work absenteeism at 4, 6, and 12 months.
Personalized Biologic Care in Practice
A 2022 review describes omalizumab as the first monoclonal antibody globally approved as a personalized treatment option for moderate-to-severe allergic asthma. It draws on almost two decades of use to address everyday clinical-practice questions about efficacy, safety, and associations with asthma-related and drug-related factors. This perspective places the treatment within a longer history of clinical use while highlighting the practical questions clinicians continue to consider.
Evidence From Patients Across Countries
A review of 24 real-life effectiveness studies included 4,117 unique patients with severe allergic asthma from 32 countries, with substantial variation among patients, clinicians, and settings. Another review examined 42 real-world studies published between 2008 and 2018 to assess omalizumab’s short- and long-term effectiveness and safety. Together, these reviews show that evidence has been gathered across diverse clinical settings and over multiple follow-up horizons. The provided adherence-study snippet says its result was consistent with other studies but does not specify the result, so it cannot support a more detailed adherence claim.
While omalizumab is not a cure for asthma, it can significantly improve the lives of those with severe allergic disease, offering them a chance to breathe easier and enjoy a better quality of life. It’s important to note that, like all medications, omalizumab may have potential side effects. However, the study found that omalizumab has an excellent long-term profile of safety and tolerability.
If you have severe allergic asthma and continue to experience frequent exacerbations or uncontrolled symptoms, talk to your doctor about whether omalizumab might be right for you. This targeted therapy could be a game-changer in managing your asthma and improving your overall well-being.